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ABSTRACT 
Purpose of review: Bisphosphonates (BPs) have long been the gold-standard anti-remodeling 
treatment for numerous metabolic bone diseases. Since these drugs are excreted 
unmetabolized through the kidney, they are not recommended for individuals with compromised 
kidney function due to concerns of kidney and bone toxicity. The goal of this paper is to 
summarize the preclinical BP work in models of kidney disease with particular focus on bone, 
kidney, and vasculature. Recent findings:  Summative data exists showing positive effects on 
bone and vascular calcifications with minimal evidence for bone or kidney toxicity in animal 
models. Summary: Preclinical data suggest it may be worthwhile to take a step back and 
reconsider the use of bisphosphonates to lessen skeletal/vascular complications associated 
with compromised kidney function. 
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Introduction 
Using bisphosphonates (BPs) in the setting of chronic kidney disease (CKD) is kind of like 
talking about politics at work – the general consensus is you just shouldn't do it. 
Bisphosphonates have long been the gold-standard anti-remodeling treatment for numerous 
metabolic bone diseases [1].  Yet because these drugs are not metabolized, kidney function 
plays a central role in the drug pharmacology [2]. BPs are not recommended for individuals with 
a creatinine clearance below 30-35 mL/min (estimated glomerular filtration rates (eGFR) lower 
than 30 ml/minute/1.73 m2) due to concern of kidney toxicity as well as drug accumulation in 
bone [3]. But what exactly is the basis for the lack of use and concern of negative effects in 
CKD? Is it evidence based, theoretical, or somewhere in between?  While companion articles in 
this issue address this question using human data, the goal of this paper is to summarize the 
preclinical BP work in CKD models with particular focus on bone, kidney, and vasculature 
(Figure 1).  
  
Bisphosphonates: Some basics 
There are more than a half dozen BPs that are FDA approved in the United States and used for 
the treatment/prevention of skeletal disease. All BPs have a common phosphate–carbon–
phosphate (P–C–P) moiety and two side chains (termed R1 and R2) as their basic structure. 
The central carbon atom confers a resistance to chemical and enzymatic breakdown while the 
two side chains, which differ among the various BPs, determine the mineral binding affinity and 
biochemical effects on osteoclast enzyme activity [4]. Early BPs did not contain a nitrogen atom 
and are often referred to as either ‘early generation’ or ‘non-nitrogen containing’ compounds 
(clodronate and etidronate are examples). More recent BPs, such as alendronate, risedronate, 
ibandronate, and zoledronate contain a nitrogen atom, and are typically referred to as ‘nitrogen-
containing’ or ‘second generation’ BPs [5]. There are a number of important differences 
between nitrogen-containing and non-nitrogen containing classes of BPs (reviewed in [4,6]) 
such that any effects (positive or negative) from one class cannot be assumed for the other. 
Beyond that, even within the newer generation BPs, there are sufficient enough differences that 
the effects from one cannot be assumed to translate to the others [5]. This becomes important 
in the setting of CKD as such little data exits that it is often confined to just one or two of the 
agents. Drug comparison studies are urgently needed in animals (and humans) with CKD.  
Skeletal accumulation of BPs 
There exists a solid foundation of data detailing how bisphosphonates accumulate and are 
cleared in animals with normal kidney function. Upon dosing, the high affinity of BPs for 
hydroxyapatite results in most of the drug becoming bound to the skeleton (reviewed here [7]). 
In healthy animals roughly 60% of administered dose is found within the skeleton 24 hours post 
dose, most of which becomes bound within the first 6 hours [8]. Any drug that is not bound is 
cleared, unmetabolized, primarily by the kidney through passive glomerular filtration and active 
secretion from the proximal tubule [2].  
The skeleton is saturable for an individual dose of BP, but not if that same dose is 
fractionated [9]. This means cumulative dose, as opposed to amount of drug given at each 
dose, is a key factor when thinking about BP accumulation in the skeleton. In addition to dose, 
the route of administration plays a significant role in determining BP levels in bone [8]. Oral 
absorption, primarily in the stomach and jejunum, is nonlinearly dose-dependent [8]. 
Intravenous dosing leads to significantly higher levels of skeletal accumulation relative to oral 
dosing. Even when bioavailability is matched between oral and intravenous dosing (giving 10-
fold higher doses orally), there is still 10-fold higher plasma concentration and a 30-fold higher 
concentration of skeletally bound BP with intravenous dosing [10]. Despite the number of 
studies that have examined the kinetics of skeletal accumulation under various conditions, there 
exists no direct evidence that levels in bone have a direct influence on physiology. That is, 
having more drug within the skeleton has not been shown to be advantageous or detrimental. In 
vitro studies clearly illustrate the potential for negative effects of accumulation, as multiple 
studies have shown that while low concentrations of BPs have beneficial effects (such as 
reduced osteocyte apoptosis), higher concentrations have negative effects (cell death) [11,12]. 
Unfortunately, there are no data from animal BP accumulation studies that present levels in 
concentrations that relate to these in vitro studies. 
Skeletal release of BP has received less attention in the literature. In vivo, 
hydroxyapatite-bound BP freely dissociates from resting surfaces and is actively liberated at 
resorption surfaces [13,14]. Data from drug withdrawal studies, in which animals are dosed with 
BPs for a period of time and then stopped, suggest that binding properties could influence 
physiological function as those with higher binding affinity have slower recovery of bone 
remodeling [15]. Yet there exists very little in vivo data documenting the dynamics of drug 
liberation from the skeleton and how it then becomes reattached or excreted over time. This is a 
significant limitation in our understanding of how levels of drug in the bone are modulated over 
time in normal animals, not to mention in animals with conditions such as CKD.  
Collectively the preclinical work highlights the complexities that intertwine both chemical 
and biological effects to determine skeletal accumulation. Furthermore, each BP has its own 
chemical and biological properties making it necessary to consider each specific drug 
individually to truly understand its pharmacokinetics and pharmacodynamics. Simply stated, the 
results from one BP are not generalizable to the others. Given this is the case and the state of 
knowledge for normal bone, it is not surprising that hesitation exists to use these drugs in 
conditions of kidney disease, where the primary route of excretion is compromised. 
 
Effects of BPs on kidney tissue and function 
Early in vitro work documented that kidney accumulation of BP occurred for first 
generation BPs (1-hydroxyethylidene—1,1 bisphosphonate; HEBP) in a time, concentration, 
and temperature dependent manner [16]. BPs passively enter kidney cells through the 
basolateral membrane and then appear to be bound in the cytosol as non-stochiometric 
‘polynuclear complexes’ with bivalent cations or as calcium complexes in the renal tubules [17]. 
This entry/binding is calcium/phosphate dependent [16] and exceeds the glomerular filtration 
rate suggesting active tubular secretion. Using newer generation BPs it has been shown that 
roughly 0.5% of an intravenous dose is retained in kidney tissue two hours post-injection; 
twenty-four hours post dose this level was 0.3% [18]. The half life of BP in the kidney tissue of 
rats is estimated to be just over three weeks [18]. 
The concern over accumulation of drug in the kidney is the potential effect it could have 
on cell function or tissue viability. In vitro experiments show that high concentrations of BPs are 
toxic to kidney cells, as they are to most cells that have been studied in culture [19]. Clodronate 
(given at supraphysiological dosages) resulted in a consistent mild to moderate proximal tubular 
necrosis after three days of treatment in rats [20]. In the same way, ibandronate produced 
tubular degeneration/single cell necrosis in a subset of animals [21]. Zoledronate yielded higher 
levels of damage with the highest doses showing tubular degeneration in the outer medullar and 
tubular atrophy in the cortex (in some cases in all animals) [21]. Both zoledronate and 
ibandroante caused hypertrophy and hyperplasia of the collecting ducts and distal tubules after 
intermittent dosing [21]. Despite these focal histopathalogical effects in some animals, changes 
in kidney function are noted only at extremely high BP doses [17,22]. It is important to note, 
however, that these doses that produce kidney damage are above and beyond those necessary 
for suppression of bone remodeling. 
 
Effects of BP on Bone in the setting of CKD 
Several experiments have been undertaken to understand how BPs affect the skeleton in the 
setting of animals with compromised kidney function. These studies have utilized an array of 
different BPs, animal models (all rodent), and outcome measures. When condensed down to a 
few clinically relevant parameters, the results are quite consistent and the gaps in knowledge 
become clear. 
 
Turnover (remodeling) 
CKD can manifest as either high or low turnover bone disease [23,24]. High turnover disease is 
driven by secondary hyperparathyroidism and the associated metabolic changes. This is the 
patient population in which BP intervention makes the most sense given their potent remodeling 
suppression efficacy. Yet there is concern that the use of BPs will result in adynamic bone – a 
term originally used to describe the histological phenotype of patients with aluminum toxicity in 
which there was no bone formation (and few to no cells) [25]. Unfortunately, this term has more 
recently been used to describe low (not absent) bone remodeling without regard to the cellular 
composition of bone. This is problematic because using the definition of low remodeling, most 
individuals on anti-remodeling treatment such as bisphosphonates (whether or not they have 
CKD) would be classified as having adynamic bone disease given that most osteoporotic drugs 
will induce 70-90% suppression of bone remodeling, yet bone cells remain. 
Bone remodeling is assessed in animals much the same as it is in humans, using 
fluorescent agents given in vivo followed by histological analysis. The main difference from the 
human assessment is the skeletal site, where long bones and vertebra are most common in 
animals, as opposed to the iliac crest in humans. Histological analysis can yield a multitude of 
outcome parameters, but the one most often used to indicate bone remodeling/turnover rate is 
bone formation rate (BFR). For sites of trabecular bone, this variable captures the formation at 
sites that are assumed to have previously undergone resorption as part of the standard coupled 
remodeling process (resorption-formation). This, along with the idea that the bone is in a steady 
state at the time when the labels are given, are two of several assumptions that are made when 
using histological assessment of bone tissue [26,27]. 
A number of animal models that display high turnover CKD have been assessed for the 
effects of BPs on bone turnover. CKD-induced models, using adenine [28] or nephrectomy (2/3 
or 5/6) [29,30], consistently show elevated trabecular bone remodeling (using BFR as a 
surrogate). Etidronate, pamidronate and ibandronate each have been shown to significantly 
reduce BFR in trabecular bone of animals with CKD. The suppression was dose-dependent, 
with some doses bringing BFR down to levels found in non-affected animals and others 
suppressing BFR beyond that of normal animals [28]. Using a progressive model of CKD, our 
group showed that a single intraperitoneal dose of zoledronate treatment (at two different doses, 
5x different than each other) over 5 weeks significantly reduced trabecular BFR to levels below 
those of untreated CKD animals and normal animals, but not significantly different than normal 
animals treated with zoledronate [31]. A follow-up study in the same animal model, extending 
the time period to 10-weeks post-dose, again documented significant reductions in BFR 
compared to untreated CKD but rates were essentially equivalent to normal untreated animals 
[32]. While the number of papers is not overwhelming, the data are consistent and clear.  When 
trabecular BFR is high in the setting of CKD, BPs effectively reduce it to levels that are 
comparable to animals with normal renal function treated with the same drug. Most importantly, 
there is no indication of adynamic bone (defined as the complete suppression of activity and 
cells). 
Treating low-turnover CKD with BPs makes less intuitive sense yet because patients can 
spontaneously transition from high to low turnover it is important to study this extreme as a 
worse case scenario. The question would be if adding BP treatment on top of a low turnover 
disease could produce true adynamic bone by suppression of cell function. The experimental 
literature, albeit limited, says no. Using the progressive CKD model, but this time with the 
addition of calcium supplementation (which lowers PTH and BFR in this model), there was 
modest additional suppression of BFR when adding zoledronate treatment [32]. Importantly, as 
seen with high turnover disease, the remodeling rates did not differ from treatment of normal 
animals or CKD animals with calcium alone. This would suggest that BPs do not push low 
turnover CKD to a state of adynamic bone, although this study used a modest dosing schedule 
(single dose assessed 10 weeks later). 
 
 
 
Volume, density, and mineralization 
Animal data concerning how BP treatment affects bone density are highly variable, in part due 
to variable effects of CKD in the animal models. Studies from each of the common models have 
documented no effect of disease on trabecular bone volume, matching multiple pieces of data 
from humans. BP treatment either has no effect [28] or leads to higher BV/TV and/or BMD [30-
34]. The effects on correcting cortical porosity are modest, although only one paper has actually 
assessed this variable [32]. This is quite surprising given the known preferential effect of CKD 
on cortical bone [35]. The effects of BP on tissue mineralization, or other aspects of the matrix 
for that matter (mineral crystallinity, heterogeneity, collagen structure/crosslinking, hydration, 
microdamage), are non-existent in part because the effects of CKD alone have only recently 
been explored [36,37]. Given that BPs are known to affect tissue properties in ways that have 
both positive and negative influence on bone integrity [38], these ultra structural assessments 
are desperately needed to understand the full picture of BP effects. 
 
Mechanical properties 
Few data exist concerning the effects of BPs on mechanical properties of CKD bone. In a 
nephrectomy model, there was no effect of pamidronate on mechanical properties of the 
femoral diaphysis, although there was also no effect of nephrectomy alone and only one 
variable was presented (ultimate load) [29]. Using the progressive CKD model, which develops 
reductions in whole bone and material mechanical properties when untreated, 5 or 10 weeks of 
zoledronate treatment failed to fully normalize femoral diaphysis properties [31,32]. In these 
same animals zoledronate was able to only partially normalize the deficits in vertebral 
mechanical properties induced by CKD [34]. Although limited, these data are somewhat 
surprising given BPs typically preserve mechanical properties of bone in rodent models of other 
diseases (such as ovariectomy or disuse). This highlights the importance of incorporating 
mechanical assessment in animal studies. Although changes in remodeling and density are 
important, ultimately the goal of treatment is to preserve mechanical integrity and animal studies 
afford a unique opportunity to actually assess mechanic properties. There is growing evidence 
from animal work that CKD has numerous effects on bone quality (reviewed in a companion 
article in this issue) and these alterations ultimately combine with the structural changes to 
determine fracture resistance.  
 
Skeletal accumulation of BP 
There are no data concerning how compromised kidney function affects skeletal accumulation 
of BPs. This is somewhat surprising given that accumulation of BP is often cited as a reason 
why these agents should not be used in patients with kidney disease. 
 
Effects of BP on Kidney function/structure in the setting of CKD 
Very little data exists regarding effects of BP on kidney structure/function in animals with altered 
kidney function. In a uni-nephrectomized rat model (young female rats) that resulted in animals 
having about a 70% reduction in kidney function, a clinically relevant dose of ibandronate was 
injected either once or 9 times (every three weeks) over an 18-week experiment. 
Concentrations of ibandronate in the kidney of normal animals were 1.6x higher in animals that 
received 9 injections compared to those who received one. Animals with compromised kidney 
function had a difference of 1.8x between the two dosing groups but, most importantly, the 
levels of drug in the kidneys of animals given 9 injections of ibandronate were significantly 
higher in animals with reduced kidney function [18]. Despite this apparent higher level of 
accumulation in renal tissue, there is no clear effect on kidney function as assessed by BUN 
[31,39] or creatinine clearance [29,30,33,40] in animals with CKD, perhaps due to the limitations 
of these biochemical markers to detect minor changes.  
 
Effects of BP on vasculature calcification 
The consequences of vascular calcification in the setting of CKD are well-established [41]. 
Given the clinical concern surrounding the use of BPs in CKD patients, the goal of all the animal 
studies focused on vascular calcification to date has been to find a BP dose that inhibits 
vascular calcification but does not affect bone remodeling. It is important to note that animal 
studies focused on vascular calcification in CKD often employ additional interventions, beyond 
nephrectomy or adenine, to promote calcification (either low protein diet or warfarin and vitamin 
D treatment). In animals with normal kidney function treated with calcification-inducing vitamin D 
and warfarin, both alendronate and ibandronate inhibit the formation of calcification, as 
assessed histologically for presence of mineral in the aortic wall [42]. In animals with CKD that 
are given calcification stimuli, ibandronate, pamidronate, and etidronate all inhibit calcification 
formation, although the latter was only found at very high doses [28,39, 43]. For both 
ibandronate and pamidronate the dose needed to inhibit vascular calcification parallel that 
needed to suppress bone remodeling [42]. This supports other evidence that there may be a link 
between vessel calcification and bone resorption. The challenge in interpreting such data is that 
these studies used doses that exceed those used clinically and they administer BP prior to the 
formation of calcification. Thus, although prevention of calcification development can be 
achieved with BPs, studies showing effects on progression would be more clinically relevant. 
Using the progressive CKD model, treatment with a single dose of zoledronate was not 
sufficient to significantly alter the higher level of aortic calcium content that develops naturally in 
this model [32].  
 Gaps in knowledge 
Assessment of the preclinical literature highlighted several gaps in our knowledge about 
bisphosphonates in the setting of CKD.  A select few of these are presented here in hopes that 
they will stimulate readers to engage in this line of research and help propel the field forward. 
 
- How is skeletal distribution of bisphosphonate affected in settings of compromised 
kidney function and does this differ among the various drugs (and routes and doses)? 
 
-Are there optimal dosing regimens that can be utilized long-term to suppress bone 
remodeling and vascular calcification while not damaging kidney function? 
 
-How do bisphosphonates work in the setting of CKD to affect tissue-level properties and 
how does this affect bone mechanical properties? 
 
-Are rodent models telling us the whole story about CKD and BPs? Given the 
preferential effects of CKD on cortical bone, and the lack of normal osteonal remodeling 
in rodents, there would seem to be value in assessing key skeletal properties 
(remodeling rate, cortical porosity, mechanics) in a large animal model of CKD treated 
with BPs. 
 
Conclusions 
Despite the prominent role of bisphosphonates in prevention/treatment of numerous skeletal 
conditions, they are notably absent in the treatment plan of patients with renal disease. In the 
introduction we posed the question of whether concerns surrounding the negative effects of 
bisphosphonates in the setting of compromised renal function were evidence based, theoretical, 
or somewhere in between? Based on the preclinical data it seems clear that the benefits are 
many and the concerns are almost all manifest only when doses far exceed those that are 
clinically relevant. There is no evidence that skeletal levels of drug reach toxic levels and no 
evidence that the level of remodeling suppression in CKD is more than that in animals without 
CKD.  Although the data on the vascular benefits are minimal – they are intriguingly positive.  
There is also no evidence that clinically-relevant doses have negative effects on kidney function 
in animal models. These data suggest it may be worthwhile to take a step back and reconsider 
using bisphosphonates to lessen skeletal/vascular complications associated with compromised 
kidney function. 
 
 
 
  
Figure Legends 
 
Figure 1.  Overview of bone, vascular and renal findings from preclinical models of chronic 
kidney disease treated with bisphosphonates.  Trabecular bone dynamic histomorphometry 
images (from animal with CKD (top) and CKD+zoledronate (bottom).  Vascular images adapted 
from [43] (from animal with CKD (right) and CKD+etidronate (left). Kidney data, depicting BUN 
(blood urea nitrate) from normal animals, animals with CKD, and animals with CKD treated with 
bisphosphonates; adapted from [32,39].  
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